Total raised
—
Last: Seed 2020-11
Stage
Seed
Founded
2020
Headcount
6
HQ
Sector
Health Tech & Life Sciences
About
A2i Therapeutics is developing novel small-molecule immuno-oncology agents. The company was formed as a joint venture between FutuRx, an Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies, and Atomwise, a US-based company using artificial intelligence for small-molecule drug discovery. The partnership will leverage Atomwise's AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target.
Funding history · 1 round · — total
2020-11
Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
oncologydrug-discoveryimmunologybiotechnology